Previous Close | 5.68 |
Open | 5.67 |
Bid | 4.10 |
Ask | 6.30 |
Strike | 112.00 |
Expire Date | 2024-05-24 |
Day's Range | 5.67 - 5.68 |
Contract Range | N/A |
Volume | |
Open Interest | 33 |
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
PBH vs. ABT: Which Stock Is the Better Value Option?
Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug (Everolimus) to support vessel healing prior to completely dissolving.